Recherche

Call +32 (0)2 555 55 55 for any department in Erasme Hospital, Jules Bordet Institute or Children's Hospital.  From today, you only need to remember one number to call all the services of the Erasme Hospital, the Jules Bordet Institute, and the Children's Hospital: +32 (0)2 555 55 55. Call this number and then simply follow our system that will send you comfortably and as quickly as possible to your wanted correspondant. 

What is Sjögren’s disease?  Sjögren’s disease (also known as Sjögren’s syndrome) is a chronic autoimmune disease characterised by the infiltration of the salivary and lachrimal glands by immune system cells (lymphocytes). This disorder of the exocrine glands explains the appearance of dry syndrome characterised by dry eyes and mouth.  Sjögren’s disease is characterised by the dysfunctioning of the exocrine glands (one speaks of “exocrinopathy”), which is the cause of the dry eyes and mouth but also dryness of the nose, throat, bronchi, skin and vaginal mucosa. This generalised dryness is very debilitating, having a negative impact on quality of life and can be the source of local complications: dry keratoconjunctivitis, oral mycosa, infection of the salivary glands, etc. Sjögren’s disease is also a systemic autoimmune disease that can affect virtually all the organs. These so-called extraglandular manifestations can result from three different mechanisms: 1/ The appearance of a lymphocytic infiltration in other tissues than the exocrine glands (primary biliary cirrhosis, renal tubular impairment, bronchial damage) 2/ autoimmune  impairment linked to the presence of immune complexes or specific autoantibodies and 3/ an uncontrolled proliferation of chronically stimulated B lymphocytes (lymphocytic interstitial pneumonia, lymphoma). Epidemiology After rheumatoid arthritis,  Sjögren’s disease is the most common connective tissue disease with a prevalence of    0.1-0.6% in the general population. It is a disease that affects primarily women (9 women for 1 man), generally aged between 40 and 50. Its appearance around the time of the menopause in women and its relatively unspecific manifestations (dryness, pain, tiredness) explain why it is often late in being diagnosed.  Clinical manifestations The trio of dryness - tiredness - pain (Sicca Asthenia Polyalgia) The trio of dryness – tiredness – pain, known by some as SAP (Sicca-Asthenia-Polyalgia) syndrome, are the main complaints expressed by patients with Sjögren’s disease. As the disease appears in the exocrine glands, it is not surprising that almost 96% of patients present eye and mouth dryness that is often very debilitating. This dryness can be more general and affect the respiratory tracts (cough) and vaginal mucosa (intimate dryness in women). More than 50% of  Sjögren’s disease patients report tiredness as a symptom. Finally, almost 1 in 2 patients have chronic joint and muscular pain without any clear anatomical cause, making it similar to fibromyalgia syndrome. These “SAP” manifestations can be very debilitating, preventing the patient from working and considerably reducing the quality of life of patients with Sjögren’s syndrome. Extraglandular manifestations of autoimmune origin Although often reduced to its symptomatic trio as set out above,  Sjögren’s disease nevertheless remains a systemic rheumatological disease of autoimmune origin that can affect any organ of the body, sometimes very seriously. In regard to this dimension, it is close to its cousin: disseminated lupus erythematosus. Sjögren’s disease can thus manifest through a Raynaud phenomenon, constitutional manifestations (fever of unexplained origin, weight loss), glandular manifestations (major swelling of the  protid and submaxillary saliva glands), ganglionary manifestations (swollen glands known as adenopathies), joint manifestations (inflammatory pain with morning stiffness for more than 30 minutes, polyarthritis),   muscular manifestations (inflammatory myositis), neurological problems (polyneuropathies, brain vasculitis, symptoms miming  multiple sclerosis), bronchial lung damage or damage to lung tissue, kidney damage (proteinuria, renal failure, glomerular lesions, tubulointerstitial lesions complicated by tubular acidosis or osteomalacia), autoimmune haematological manifestations (anaemia, thrombocytopenia, leukopenia) and biological haematological manifestations (cryoglobulinemia, complement consumption, hypergammaglobulina). Non-Hodgkin’s lymphoma The intense activation of the immune system can lead to a major increase in B lymphocytes. If these lose their regulating mechanism, a B cell sub-population will continue to proliferate without limit: this is a cancer of the immune system, known as non-Hodgkin’s lymphoma. It is a complication found in between 5 and 10% of Sjögren’s disease patients. Generally slow to develop and quite discreet, it should be sought in the case of a chronic unilateral swelling of a salivary gland, adenopathies or an unexplained fever, for example. The rheumatologist may screen persons at risk of developing a lymphoma subsequent to  Sjögren’s disease by searching for clinical and biological anomalies reflecting the appearance of an excessive B-cell proliferation and monitor them more closely.  Diagnosis Due to its frequent non-specific manifestations  - tiredness, pain and dryness – and its systemic manifestations that can be polymorphous (neurological, kidney, lung, skin disorders, etc.) Sjögren’s disease can be complicated to diagnose.  In addition, there is not at present any single test that permits a diagnosis. The diagnosis is based on a set of clinical and biological arguments:  Subjective dryness of the eyes and mouth; Objectification of an impaired functioning of the salivary and lachrimal glands   - Establishing of damage to the surface of the eye by an ophthalmologist ; - Establishing of a reduced lachrimal flow by the Schirmer test; - Establishing of a reduced salivary flow by a sialometry; - Establishing of a malfunctioning of the salivary glands by a scintigraphy; - Establishing of MRI or ultrasound anomalies in the salivary glands. Lymphocytic Infiltration on a biopsy of accessory salivary glands; Establishment of anti-Ro/SSA and/or anti-La/SSB autoantibodies in the blood. Treatment There is not at present any curative treatment for Sjögren’s disease. Treatment is based on 3 dimensions: The dryness syndrome, tiredness and chronic pain (evaluated by the ESSPRI score) are treated on a  symptomatic and multidisciplinary basis in cooperation with the Departments of Ophthalmology and Physiotherapy and the Pain Clinic. The initial evaluation aims to exclude the involvement of certain manifestations systemic to tiredness and pain  (hypothyroidism, osteomalacia, lymphoma) as well as to identify persistent limiting factors (sleeping problems, depression, kinesiophobia, etc.) before proposing a multimodal treatment.  These interventions include prescribing artificial tears or saliva and the use of eye drops based on an autologous serum.  Pilocarpin is also a medication commonly prescribed to permit an increase in tear or saliva secretions. Sjögren’s disease is recognised as a “serious pathology” that brings the entitlement to 60 physiotherapy sessions a year. Following a diagnosis by your rheumatologist your mutual insurance company can also grant you monthly financial assistance to purchase eye drops and other medicines against dryness. Extraglandular manifestations of an autoimmune origin (evaluated with the aid of the ESSDAI score) can be present to very variable degrees. Depending on the organs affected and the seriousness of the inflammation, an immune suppression / immune modulator treatment may be prescribed by the rheumatologist: corticoids (Médrol), hydroxychloroquine (Plaquenil), méthotrexate, azathioprine, mycophenolate mofetil, rituximab or cyclophosphamide. Within our institution, the multidisciplinary treatment of complex systemic diseases   - of which Sjögren’s disease is one – is one of the missions  of the  MISIM (Immuno-Mediated Systemic Inflammatory Diseases) platform that includes rheumatologists, general internists, nephrologists, pneumologists, dermatologists... with a penchant for and expertise in autoimmune diseases. Sjögren’s  disease – apart from the intense activation of B lymphocytes – can be complicated in certain patients by a non-Hodgkin’s lymphoma (cancerous proliferation of the lymphocytes). This risk is the reason for at least an annual clinical and biological follow up in patients with Sjögren’s disease. If a lymphoma appears  in a patient being monitored for Sjögren’s disease, the patient will be monitored in cooperation with our hospital’s Department of Haematology.   

What are sleep apnea? As the name indicates, sleep apnea is when breathing stops, for at least 10 seconds, during sleep. If this happens more than five times an hour, you are no doubt suffering from obstructive sleep apnea-hyponea syndrome (OSAHS).    OSAHS is often but not always accompanied by snoring. In any event, it affects the quality of sleep. Not only do persons with this condition wake up feeling tired, but in the longer term OSAHS has a series of physiological and/or psychological consequences that can give rise to cardiovascular, pulmonary, metabolic, haematological, psychiatric (depression) or cognitive (memory and concentration problems, etc.) complications. Far from being inconsequential, OSAHS impairs the quality of life and brings a risk of premature death.    Care Some specialist doctors at the H.U.B have particular expertise in sleep disorders. These are mainly psychiatrists, ENT specialists, pneumologists, neurologists or even stomatologists. These specialists can prescribe a polysomnography or sleep test at the H.U.B. Sleep Laboratory.    What are the procedures for a sleep test?    You generally arrive at the Sleep Laboratory at around 2 pm. A member of staff will show you to a private room. Before lying down you are fitted with a number of sensors connected to various measuring devices. Depending on the case, a video camera may record you during the night. This enables the team to detect any abnormal movements (sleepwalking,  epilepsy, etc.), to ensure you are safe in the event of nocturnal restlessness and to reconnect any sensor that may become detached during your sleep.    The next day the numerous data collected are analysed. This analysis makes it possible to confirm the OSAHS diagnosis and/or identify any other sleep disorders. A secondary assessment by another specialist doctor is sometimes necessary.    Treatment  Depending on the causes, origin and seriousness of the OSAHS, various treatment is possible:    People with OSAHS caused by sleeping on their back are offered positional therapy to correct their sleeping positions.    As being overweight or obese is the number one risk factor for OSAHS, patients are always advised to lose weight.     Alcohol, smoking and taking myorelaxant drugs (such as benzodiazepines) can also aggravate OSAHS. Patients can therefore be directed towards specialised care to help them reduce or stop the use of these substances.    The Continuous Positive Airway Pressure (CPAP) machine is a mask, usually nasal, that is worn during the night to correct apnea.      A mandibular advanced orthosis is generally indicated for a mild to moderate OSAHS (< 30 apneas/hour). This orthosis is made to measure in the Department of Stomatology   Maxillofacial surgery makes it possible to correct in apnea sufferers the position of the mandible (lower jaw) and of the maxillary (upper jaw) and is recommended for moderate to severe OSAHS  (> 30 apneas/hour).           Image Research The H.U.B Sleep Laboratory participates in a number of studies. An important line of research is the connection between sleep disorders and certain cardiovascular and neurological diseases (MS, Parkinson’s, etc.), the polysomnographic markers of certain pathologies, etc.    

What is slow digestion? Slow digestion, or gastroparesis, is a disorder characterized by delayed gastric emptying. It can cause symptoms such as nausea, bloating, early satiety, or abdominal pain. This condition may be related to underlying diseases such as diabetes or may appear without an apparent cause. Erasme Hospital offers innovative solutions to improve gastric emptying and reduce symptoms. Slow digestion: what medical care is available at H.U.B? The Gastroenterology Department of Erasme Hospital offers an advanced approach to treating slow digestion, combining precise diagnosis with modern therapeutic options. Among innovative treatments, Botox injection into the pylorus helps relax the muscle and speed up the passage of food. Another alternative is the G-POEM procedure (Gastric Per-Oral Endoscopic Myotomy), which involves partially cutting the pyloric muscle to sustainably improve gastric emptying.Our multidisciplinary team, composed of gastroenterologists, radiologists, dietitians, and physiotherapists, provides personalized follow-up for each patient to optimize outcomes and improve quality of life.Patients suffering from slow digestion can improve their digestive comfort by adopting certain habits: choosing smaller, more frequent meals, preferring easily digestible foods, and chewing food thoroughly. Regular hydration and light physical activity, such as walking after meals, can also help. If symptoms persist, a medical consultation is recommended. Discover the Gastroenterology Department of H.U.B Slow digestion: what scientific and medical innovations are available at H.U.B? Erasmus Hospital is a reference center for research on digestive motility disorders. Our teams participate in clinical studies on innovative treatments such as Botox and G-POEM to optimize their effectiveness and develop new approaches. Our goal is to offer patients effective and minimally invasive solutions to improve their digestive comfort. Our Contributions to Scientific Research As members of a leading academic hospital, our healthcare professionals conduct scientific research projects to advance medicine and continuously improve the quality of care provided to patients. View the list of our scientific publications

To ensure you are fully informed about the procedure, please read this information carefully. Your doctor is available to provide any additional details you may require. How to prepare for a small bowel examination with a video capsule? Video capsule examination of the small bowel has been available for several years, but since July 2008 it has only been reimbursed by the INAMI/RIZIV at 75% (APPROXIMATELY €200 to be paid by the patient).The day before the examination, the patient should:Follow a low-fiber diet, meaning no fruits or vegetables (neither cooked nor raw), and no whole wheat or brown bread. You may eat white bread, white pasta, meat, and dairy products.Drink a preparation: purchase a box of PLENVU from a pharmacy (available without a prescription). Around 5:00 PM, have your evening meal. Around 6:00 PM, start the PLENVU: take dose 1, mixed in ½ liter of water (to be drunk within 30 minutes); then drink another ½ liter of clear liquid of your choice.From midnight: remain fasting.On the day of the examination:Remain fasting from midnight.Go to the 1st floor at the Endoscopy Unit, Route 306.If this is your first visit to ERASME Hospital, please first check in at the consultation reception in the hospital lobby.You will swallow the video capsule with a glass of water; the capsule is the size of a medicine capsule (water + 20 ml Endo-Paractol).A belt with a recording device will be fastened around your waist.You will stay in the rest area for 1 hour after swallowing the capsule to ensure it has reached your duodenum.If the capsule is still in the stomach, you will receive a 10 mg Motilium tablet.You may drink water 1 hour after ingesting the capsule, and then eat and drink normally 3 hours after ingestion.Around 4:30 PM, return to the Endoscopy Unit on the 1st floor (Route 306), where the belt with the recording device will be removed.The video capsule will be eliminated in the stool and does not need to be retrieved. N.B.: Do not undergo an MRI (magnetic resonance imaging) on the day of the examination or in the days following.For any information or in case of cancellation, please contact the Endoscopy Clinic by phone at +32 (0)2 555.32.92 or by email at rendez-vous [dot] Endoscopie [dot] erasme [at] hubruxelles [dot] be

The Social Services Department accompanies patients and families by proposing psychosocial support, advice and resources within your care pathway. This accompaniment can take the form of putting into place a discharge project (return home, rehabilitation, admission to a rest home, etc.) as well as assistance with the various social and administrative procedures.  If you have any questions, please feel free to contact: For the Erasmus Hospital Secretariat Tel : +32 2 555 34 73 E-mail : ServiceSocial [dot] erasme [at] hubruxelles [dot] be (ServiceSocial[dot]erasme[at]hubruxelles[dot]be) For the Traumatology and Rehabilitation Centre (CTR) Aurélie Dagorn E-mail : aurelie [dot] dagorn [at] hubruxelles [dot] be (aurelie[dot]dagorn[at]hubruxelles[dot]be) For the Geriatric Rehabilitation Centre (CRG) Gregoire Gasmanne E-mail : gregoire [dot] gasmanne [at] hubruxelles [dot] be (gregoire[dot]gasmanne[at]hubruxelles[dot]be)

Practical information Service location: Erasmus Hospital (general hospital), level -1: follow route 671.5 intensive care units: Unit 1-2-3-4-5Visiting hours: 2:30 pm to 7:30 pm: maximum of 2 visitorsIs one of your relatives admitted or due to be admitted to the Intensive Care Unit of Erasmus Hospital?Intensive care reception: 02/555.33.95 (10 am–6 pm) or admissions department: 02/555.16.78.You will find other useful information about our service by clicking here.Are you a general practitioner and would you like to obtain the medical results of your patients?secmed [dot] usi [dot] erasme [at] hubruxelles [dot] be Continuous care for the most vulnerable patients Our department provides multidisciplinary care for patients. These include hospitalized patients or patients referred from the emergency department or the operating room who are in critical condition and require continuous close monitoring, 24 hours a day, 7 days a week. We deliver this care with respect for patients’ autonomy and wishes, without any discrimination based on their condition or beliefs. Image Image Image Image Conditions managed exclusively in the Intensive Care Unit of the H.U.B. Acute neurological care: traumatic brain injuries, cerebral hemorrhages, unexplained coma, stroke, epilepsy, …Acute cardiological care: cardiac arrest and post–cardiac arrest care, arrhythmias, heart failure and circulatory support (LVAD, heart transplantation, ECMO)Thromboembolic diseases (in collaboration with the Pulmonary Embolism Response Team Erasme), pulmonary hypertensionTransplant patients (cardiac, pulmonary, hepatic, renal, pancreatic, …)ARDS (veno-venous ECMO), complex ventilator weaning in collaboration with the pulmonology departmentPulmonary fibrosisComplex thoracic surgery: postoperative follow-upLiver cirrhosis and acute liver failureAcute or chronic renal failureSickle cell diseaseOnco-hematology Image Care services offered by the Intensive Care Unit of the H.U.B. The department brings together specialized staff (physicians, nurses, physiotherapists, …) and the specific equipment required for the monitoring and treatment of critical illnesses.Comprehensive management of patients suffering from organ failurePersonalized care pathways following an acute eventHolistic approach to care in collaboration with a dietitian, a psychologist, an occupational therapist, physiotherapists, nursing assistants, and the hospital’s medical specialistsRegular communication with patients’ familiesInnovations: post–intensive care consultation, possibility of animal-assisted contact with the unit’s dog (Yuki) under strict hygiene conditions, “Green ICU”, … Intensive Care at H.U.B.: key figures Number of patients treated 2.800 each year Number of transplants 190 per year Number of extracorporeal membrane oxygenation (ECMO) procedures 40 per year Prof. Fabio Taccone, Head of the Intensive Care Department Prof. Fabio Silvio Taccone is Professor of Intensive Care Medicine and Head of the Intensive Care Department at the Brussels University Hospital (H.U.B. – Erasmus Hospital). He received his medical training in Italy and specialized in internal medicine and intensive care in Belgium. He then pursued his academic and clinical career at H.U.B., where he is now internationally recognized as an expert in intensive care medicine. His main areas of expertise include neurocritical care (traumatic brain injury, subarachnoid hemorrhage, stroke), the management of sepsis and septic shock, advanced hemodynamic support, and multimodal monitoring techniques in critical care. He is the author or co-author of more than 900 indexed scientific publications and has participated in numerous international multicenter clinical trials. He is an active member of several scientific societies, including the ESICM (European Society of Intensive Care Medicine), and regularly contributes to international guidelines and consensus statements. As department head, he combines clinical, academic, and research activities, with a strong commitment to training young intensivists and disseminating knowledge. He is also involved in organizing leading international conferences such as ISICEM (International Symposium on Intensive Care & Emergency Medicine). Our team Image Our intensivists Filippo AnnoniGilles BoumazaCharles Dehout  Côme GarinJulie GorhamVincent LabbéRaphaël LarsenMehdi MezidiAnthony MoreauRaphaël MottaleLeda NobileZoé PletschetteChahnez TalebMichael WatchiKatarina Winant-Halenarova  Head nurses:ICU 1: Daniele ColluraICU 2: Gaetan CrohinICU 3: Laetitia GeldhofICU 4: Nathalie BaillyICU 5: Gwenaelle MercierChristian VanderwallenHead Nurse of the DepartmentYves MaetensChief PhysiotherapistFrédéric BonnierPsychologistAraxie MatossianDietitianGabrielle BonneIntensive Care ReceptionFlorence AbrassartLaura JacminDepartment dogYuki Our scientific publications Lien vers https://www.nejm.org/doi/full/10.1056/NEJMoa2214552 Mild Hypercapnia or Normocapnia after Out-of-Hospital Cardiac Arrest Eastwood G, Nichol AD, Hodgson C, Parke RL, McGuinness S, Nielsen N, Bernard S, Skrifvars MB, Stub D, Taccone FS, Archer J, Kutsogiannis D, Dankiewicz J, Lilja G, Cronberg T, Kirkegaard H, Capellier G, Landoni G, Horn J, Olasveengen T, Arabi Y, Chia YW, Markota A, Hænggi M, Wise MP, Grejs AM, Christensen S, Munk-Andersen H, Granfeldt A, Andersen GØ, Qvigstad E, Flaa A, Thomas M, Sweet K, Bewley J, Bäcklund M, Tiainen M, Iten M, Levis A, Peck L, Walsham J, Deane A, Ghosh A, Annoni F, Chen Y, Knight D, Lesona E, Tlayjeh H, Svenšek F, McGuigan PJ, Cole J, Pogson D, Hilty MP, Düring JP, Bailey MJ, Paul E, Ady B, Ainscough K, Hunt A, Monahan S, Trapani T, Fahey C, Bellomo R; TAME Study Investigators. N Engl J Med. 2023 Jul 6;389(1):45-57. doi: 10.1056/NEJMoa2214552. Epub 2023 Jun 15. Lien vers https://www.nejm.org/doi/full/10.1056/NEJMoa2115998 Treating Rhythmic and Periodic EEG Patterns in Comatose Survivors of Cardiac Arrest Ruijter BJ, Keijzer HM, Tjepkema-Cloostermans MC, Blans MJ, Beishuizen A, Tromp SC, Scholten E, Horn J, van Rootselaar AF, Admiraal MM, van den Bergh WM, Elting JJ, Foudraine NA, Kornips FHM, van Kranen-Mastenbroek VHJM, Rouhl RPW, Thomeer EC, Moudrous W, Nijhuis FAP, Booij SJ, Hoedemaekers CWE, Doorduin J, Taccone FS, van der Palen J, van Putten MJAM, Hofmeijer J; TELSTAR Investigators. N Engl J Med. 2022 Feb 24;386(8):724-734. doi: 10.1056/NEJMoa2115998. Lien vers https://www.nejm.org/doi/full/10.1056/NEJMoa2100591 Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest Dankiewicz J, Cronberg T, Lilja G, Jakobsen JC, Levin H, Ullén S, Rylander C, Wise MP, Oddo M, Cariou A, Bělohlávek J, Hovdenes J, Saxena M, Kirkegaard H, Young PJ, Pelosi P, Storm C, Taccone FS, Joannidis M, Callaway C, Eastwood GM, Morgan MPG, Nordberg P, Erlinge D, Nichol AD, Chew MS, Hollenberg J, Thomas M, Bewley J, Sweet K, Grejs AM, Christensen S, Haenggi M, Levis A, Lundin A, Düring J, Schmidbauer S, Keeble TR, Karamasis GV, Schrag C, Faessler E, Smid O, Otáhal M, Maggiorini M, Wendel Garcia PD, Jaubert P, Cole JM, Solar M, Borgquist O, Leithner C, Abed-Maillard S, Navarra L, Annborn M, Undén J, Brunetti I, Awad A, McGuigan P, Bjørkholt Olsen R, Cassina T, Vignon P, Langeland H, Lange T, Friberg H, Nielsen N; TTM2 Trial Investigators. N Engl J Med. 2021 Jun 17;384(24):2283-2294 Lien vers https://jamanetwork.com/journals/jama/fullarticle/2824930 Restrictive vs Liberal Transfusion Strategy in Patients With Acute Brain Injury: The TRAIN Randomized Clinical Trial Taccone FS, Rynkowski CB, Møller K, Lormans P, Quintana-Díaz M, Caricato A, Cardoso Ferreira MA, Badenes R, Kurtz P, Søndergaard CB, Colpaert K, Petterson L, Quintard H, Cinotti R, Gouvêa Bogossian E, Righy C, Silva S, Roman-Pognuz E, Vandewaeter C, Lemke D, Huet O, Mahmoodpoor A, Blandino Ortiz A, van der Jagt M, Chabanne R, Videtta W, Bouzat P, Vincent JL; TRAIN Study Group. JAMA. 2024 Nov 19;332(19):1623-1633 Research in Intensive Care Ongoing clinical studiesEsScape 996Multicenter phase III study evaluating the efficacy and safety of trimodulin versus placebo in adult hospitalized patients with community-acquired pneumonia requiring mechanical ventilation.Secondary objectives include detailed assessment of pharmacokinetic (PK) properties in a sub-study and evaluation of pharmacodynamic properties.Sponsored by Biotest AG.BONANZAInternational multicenter ICU study aiming to reduce cerebral hypoxia following severe traumatic brain injury. The study evaluates whether optimization of cerebral oxygenation management using a brain monitoring catheter, compared with standard care based solely on intracranial pressure monitoring, improves neurological outcomes at 6 months.In collaboration with Monash University (New Zealand).BTI-203Randomized, double-blind, placebo-controlled phase II study assessing the efficacy and safety of recombinant human plasma gelsolin as an adjunct to standard therapy in moderate to severe acute respiratory distress syndrome (ARDS) due to pneumonia or other infections.Sponsor: BioAegis Therapeutics, Inc.CAFSRandomized controlled trial comparing three management strategies (risk control, heart rate control, and rhythm control) for de novo supraventricular arrhythmias during septic shock in adult patients. The primary endpoint is a hierarchical outcome combining mortality and duration of septic shock. Secondary endpoints include rhythm control efficacy, morbidity and mortality, and tolerance.Study conducted by AP-HP (France).EPO-TRAUMARandomized, double-blind, multicenter trial comparing erythropoietin alfa versus placebo in severely traumatized mechanically ventilated patients. The primary endpoint is mortality and severe disability at 6 months.Conducted in collaboration with Monash University (New Zealand).LATTEClinical study evaluating the impact of hypertonic sodium lactate administration in patients surviving cardiac arrest who remain unconscious.Funded by the European Society of Intensive Care Medicine (ESICM) and the Erasme Fund for Medical Research.OXYTRIPInternational, multicenter, randomized controlled study comparing two transfusion strategies in ICU patients: a “standard” strategy (target hemoglobin ≤ 9 g/dl according to international guidelines) versus a “targeted” strategy (target hemoglobin ≤ 7 g/dl to optimize oxygen debt).Initiated by the University of Ferrara (Italy).PRINCESS 2Prehospital Resuscitation Intranasal Cooling Effectiveness Survival Study. International multicenter study investigating whether early therapeutic hypothermia in out-of-hospital cardiac arrest improves survival and neurological recovery. Brain cooling is initiated on-site using intranasal cooling (RhinoChill) versus standard resuscitation with normothermia maintained for 72 hours in ICU.In collaboration with Karolinska Hospital (Stockholm, Sweden).PRO-ACTMulticenter, randomized, double-blind study evaluating probiotics versus placebo to reduce ventilator-associated pneumonia in brain-injured or stroke patients in ICU.STEPCAREInternational multicenter study on post-resuscitation care in unconscious patients after out-of-hospital cardiac arrest. The goal is to determine the optimal combination of sedation, temperature, and blood pressure management to improve survival and limit neurological sequelae.Study sponsor: Helsingborg Hospital.STRADA-CEFNational multicenter study evaluating stratified ceftriaxone dosing based on augmented renal clearance in hospitalized patients with severe community-acquired pneumonia. The aim is to assess the impact of adjusted dosing on length of stay.Initiated by UZ Leuven.TELSTAR 2Randomized, multicenter clinical trial with medico-economic evaluation of anti-epileptic drug treatment in comatose patients after cardiac arrest presenting with status epilepticus on continuous EEG. The study assesses whether anti-epileptic therapy improves recovery.Conducted by the University of Twente (Netherlands).TRECRandomized multicenter study evaluating red blood cell transfusion thresholds (liberal ≤ 9 g/dl Hb vs restrictive ≤ 7 g/dl Hb) in patients receiving ECMO. The primary endpoint is 90-day mortality.Conducted by Amsterdam UMC.VENTILORandomized, controlled, multicenter trial comparing non-invasive ventilation with high-flow nasal oxygen in post-extubation respiratory failure. The primary endpoint is 28-day mortality.Sponsor: Poitiers University Hospital (France). Intensive Care Education at H.U.B. Our academic department welcomes healthcare professionals in training from all medical and paramedical disciplines on a daily basis. Teaching takes place at the patient’s bedside as well as through numerous seminars and practical training sessions using simulation.